Ovid Therapeutics Inc. · NASDAQ:OVID

Ovid Therapeutics — Investor Presentation (August 2021)

21 slides from Ovid Therapeutics's investor presentation, Aug 18, 2021

  1. Slide 1: Ovid Therapeutics Corporate Overview August 2021

    Ovid Therapeutics Corporate Overview August 2021 AUGUST 2021 ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED Exhibit 99.1

  2. Slide 2: Disclaimers and Forward-Looking Statements

    Disclaimers and Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “may,” “will,” “believe,” “expect,” “plan,” “anticipate” and similar expressions (as well as other words or expre

  3. Slide 3: Strong Foundation For Successful Neurosciences Development

    Strong Foundation For Successful Neurosciences Development Build a unique company that delivers first-in-class therapeutics for rare disorders of the CNS 1 As of 6/30/21 2 Excluding non-cash and non-recurring expenses 3 As of 6/30/21, on an as if converted basis THE RIGHT TEAM PROVEN TRACK-RECORD IN

  4. Slide 4: Ovid Therapeutics Focus & Approach

    Ovid Therapeutics Focus & Approach Developer of novel first-in-class / best-in-class therapeutics that seek to make a BOLD impact in rare neurological and related CNS disorders. 4 FOCUS Translation engine Target identification, pathology & translation with academic partners APPROACH Modality & deliv

  5. Slide 5: Pipeline Overview: Advancing Treatments for Rare Neurologic Diseases

    Pipeline Overview: Advancing Treatments for Rare Neurologic Diseases 5 AUGUST 2021 ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED Phase 3 Planned Initiation 2021 Phase 3 Planned Initiation 2021 Anticipate filing three INDs in three years, beginning 1H 2022

  6. Slide 6: Soticlestat Agreement with Takeda Holds Potential to Generate Up to $856M

    Soticlestat Agreement with Takeda Holds Potential to Generate Up to $856M Upfront Payment $196M received at closing All financial obligations to Takeda for soticlestat are terminated Regulatory Milestones Regulatory milestones Takeda funding two comprehensive pivotal trials (LGS and Dravet) Commerci

  7. Slide 7: Rare Neurologic Conditions Represent Significant Opportunity

    Rare Neurologic Conditions Represent Significant Opportunity Yet, CNS drug development has been historically challenged Incomplete understanding of disease biology Poor predictive value of animal models Lack of reliable biomarkers and difficult-to measure endpoints Blood-brain-barrier preventing the

  8. Slide 8: Recent Scientific Advances and CNS Expertise Enable Development for Previously Undruggable Targets

    Recent Scientific Advances and CNS Expertise Enable Development for Previously “Undruggable” Targets Recent successes in genetic medicine paves the path for next-gen therapies: Next-gen DNA and RNA editing tech Immune system modulation Understanding of functional genomics Molecular imaging and funct

  9. Slide 9: Business Development Activities Support Our Approach

    Proprietary and differentiated enabling technologies and delivery systems to support development of next-generation CNS therapeutics Tools that can be applied and offer utility for current pre-clinical and future CNS assets Assays that support penetration across the blood brain barrier, and allow in

  10. Slide 10: Pipeline Candidates: A closer look

    Pipeline Candidates A closer look AUGUST 2021 ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED

  11. Slide 11: Pipeline Overview: Advancing Treatments for Rare Neurologic Diseases

    Pipeline Overview: Advancing Treatments for Rare Neurologic Diseases 11 AUGUST 2021 ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED Phase 3 Planned Initiation 2021 Phase 3 Planned Initiation 2021 Anticipate filing three INDs in three years, beginning 1H 2022

  12. Slide 12: OV329 Overview: Highly Potent Inhibitor of GABA Aminotransferase

    Indication(s): Refractory Epilepsies 1. Tuberous sclerosis complex Affects 1 in 6K individuals (~50K patients in US); epilepsy present in ~85% of TSC patients* Current treatment options include vigabatrin, everolimus, and surgery Significant unmet need: Most patients resistant to current therapy 2.

  13. Slide 13: OV329 Appears Active in Models of Drug-Resistant Seizures

    OV329 Appears Active in Models of Drug-Resistant Seizures Orally delivered OV329 as effective as injectable SOC in infantile spasms model NMDA Model described by Shi et al., 2014 (PMID 26600368) 13 AUGUST 2021 ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED

  14. Slide 14: OV882 Overview: Potential Disease-Modifying Genetic Therapy for Angelman Syndrome

    Indication: Angelman Syndrome Affects 1 in 15K individuals Characterized by developmental delay, ataxia, sleep disorder, seizures, and speech impairments Current treatment options are symptomatic (e.g., anti-seizure) Significant unmet need: No specific treatments available which target the neuropath

  15. Slide 15: OV882 Approach to the Treatment of Angelman Syndrome

    OV882 Approach to the Treatment of Angelman Syndrome DISEASE STATE ASO APPROACH OV882 shRNA APPROACH Mechanism may cause undesirable off-target effects Requires redosing on approximately quarterly timescale Requires chemical modification of ASO Angelman syndrome is caused by a mutation in the matern

  16. Slide 16: OV882 Appears Active in Pre-Clinical AS Neuron Cell Model

    OV882 Appears Active in Pre-Clinical AS Neuron Cell Model OV882 demonstrates activity in AS neuronal cell system: >2x increase in UBE3A mRNA expression when compared to SCRAM control Reduction in UBE3A-ATS expression further demonstrates the potential mechanism and efficacy of OV882 16 AUGUST 2021 ©

  17. Slide 17: OV815 Overview: Potential Advanced Genetic Therapy for KAND

    Indication: KAND* ~200** patients worldwide with documented diagnoses; total number of affected patients likely in the thousands Broader kinesin superfamily opportunity Symptoms associated with KAND include hereditary spastic paraplegia, ataxia, epilepsy, hypotonia, autism, and ADHD Current treatmen

  18. Slide 18: OV815 Has Potential For Broader Applicability Within the Kinesin Superfamily

    OV815 Has Potential For Broader Applicability Within the Kinesin Superfamily Impact of KIF1A on neurotransmission KIF1A is a motor protein that transports cargo for neurons Disruption of cargo transport impacts neurotransmission and leads to progressive neurologic deficits Additional opportunities i

  19. Slide 19: Proven Business Development Track Record

    Strong history of identifying promising targets in hard-to-treat diseases Proven Business Development Track Record Monetized CNS expertise to strengthen the balance sheet and create a potential cash stream to build the next major player in CNS DECEMBER 2016 License agreement w/Northwestern for OV329

  20. Slide 20: The Ingredients to Be a Major Player in CNS

    The Ingredients to Be a Major Player in CNS 20 Modality & delivery mechanisms to cross the BBB Enabling technologies & screening tools increase efficiency Effective prosecution of R&D; coupled with pipeline acquisitions THE OVID APPROACH Apply insights from small molecule neurologic therapeutics to

  21. Slide 21: Thank you

    Thank you August 2021 AUGUST 2021 ©2021 OVID THERAPEUTICS INC. | ALL RIGHTS RESERVED

Ovid Therapeutics — Investor Presentation (August 2021) on 6ix